Nucleome Therapeutics raises oversubscribed £37.5 million Series A

Nucleome Therapeutics Limited, a biotechnology company decoding the dark matter of the human genome to discover first-in-class precision medicines, announces it has closed an oversubscribed £37.5 million Series A financing round. The funds will be used to advance the Company’s autoimmune disease programmes, fuel expansion of its dark genome atlas and further develop its pioneering platform.

Nucleome has the unique ability to discover and validate first-in-class targets through genetics, by investigating the ‘dark’ region of the human genome, which does not encode for proteins but contains 90% of disease-associated genetic changes. Understanding the role of these genetic variants has been a long-standing challenge, hindering the translation of the human genome into useful drug discovery insights.

Nucleome’s breakthrough platform combines pioneering 3D genome technology and machine learning to shed light on these variants by directly linking genes to diseases and mapping pathways with unprecedented precision for drug discovery.

“We have already made significant progress by mapping genes to genetics in a number of human immune cell types and discovering the first wave of potential first-in-class autoimmune disease targets,” said Dr Danuta Jeziorska, Chief Executive Officer and Co-founder of Nucleome Therapeutics.  “

Click here to find out more.

Recent news

Oxford North tops out and unveils new park name

Oxford North tops out and unveils new park name

Oxford North, the new innovation district in Oxford, has reached its highest point in construction and topped out its first phase with the Red Hall’s new cantilever roof lowered into place, and two new lab buildings' steel frames completed.   Oxford North is the...

read more
Grove Business Park joins Advanced Oxford

Grove Business Park joins Advanced Oxford

Advanced Oxford is delighted to welcome Grove Business Park in Wantage as a new sponsor member, who will be actively contributing to our work in supporting the development of Oxfordshire’s innovation ecosystem. Grove Business Park is owned by The Oxford Endowment Fund...

read more
Loading...